Wednesday, July 8, 2026

biotech · Dental Caries · Cystic Fibrosis · ARMP

Armata Pharmaceuticals

Armata Pharmaceuticals clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Freehold, USA HQ
2018 Founded
18 Employees
Public company Type
ARMP · NYSE Ticker
Company details
Status
Public
HQ
Freehold, USA
Founded
2018
Employees
18
Programs
9
Drugs
0
Patents
5
Intelligence · Clinical Programs

Armata Pharmaceuticals projects

9 ClinicalTrials.gov programs sponsored by Armata Pharmaceuticals.

Armata Pharmaceuticals has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AP-PA02

    Armata Pharmaceuticals

    Non-cystic Fibrosis Bronchiectasis

    phase 2 mab completed

    1 trial
  2. AP-PA02

    Armata Pharmaceuticals

    Cystic Fibrosis

    phase 2 mab completed

    1 trial
  3. AP-SA02

    Armata Pharmaceuticals

    Bacteremia

    phase 2 mab completed

    1 trial
  4. C16G2

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    3 trials
  5. C16G2 Gel

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    1 trial
  6. C16G2 Rinse

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    1 trial
  7. C16G2 Strip

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    1 trial
  8. C16G2 Varnish

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    1 trial
  9. AB-SA01 (10^8 PFU per phage)

    Armata Pharmaceuticals

    Healthy Volunteers

    phase 1 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Armata Pharmaceuticals have?

9 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.